Author Affiliations: University of Texas School of Public Health, Houston (Dr Moyé; firstname.lastname@example.org); Mayo Clinic, Rochester, Minnesota (Dr Simari); and National Heart, Lung, and Blood Institute, Bethesda, Maryland (Dr Skarlatos).
To the Editor: We would like to clarify several points in the Editorial1 accompanying the report of the Timing In Myocardial infarction Evaluation (TIME) trial.2
First, the automated system for extracting bone marrow–derived mononuclear cells (MNCs) used for the Cardiovascular Cell Therapy Research Network's (CCTRN’s) clinical trials uses Ficoll gradient centrifugation,3 which is similar to the manual method used more commonly.
Moyé LA, Simari RD, Skarlatos SI, Cardiovascular Cell Therapy Research Network (CCTRN) FT. Bone Marrow–Derived Cell Therapy After Myocardial Infarction. JAMA. 2013;309(14):1459-1460. doi:10.1001/jama.2013.2601